Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2000, p. 2039-2045, Vol. 44, No. 8
Departments of Anatomy, Cell Biology and
Injury Sciences1 and Microbiology and
Molecular Genetics,3 University of Medicine and
Dentistry of New Jersey-New Jersey Medical School and Graduate School
of Biomedical Sciences, Newark, New Jersey, and Infectious
Disease Section, Veterans Affairs Medical Center, Houston,
Texas2
Received 25 February 2000/Returned for modification 21 April
2000/Accepted 11 May 2000
Antimicrobial peptides are proposed to act as the first line of
mucosal host defense by exerting broad-spectrum microbicidal activity
against pathogenic microbes. Pleurocidin, a new 25-residue linear
antimicrobial peptide, was recently isolated from the skin secretions
of winter flounder (Pleuronectes americanus). The present study identifies the cDNA and gene encoding pleurocidin. The
pleurocidin gene comprises four exons. Its upstream region demonstrates
consensus binding sequences for transcription factors found in host
defense genes in mammals, including sequences identical to the NF-IL6 and alpha and gamma interferon response elements. Pleurocidin is
predicted to exist as a 68-residue prepropeptide that undergoes proteolytic cleavage of its amino-terminal signal and carboxy-terminal anionic propiece to form the active, mature peptide. Transmission electron microscopy localized pleurocidin to the mucin granules of skin
and intestinal goblet cells. Significant synergy was shown to occur
between pleurocidin and D-cycloserine targeting
Mycobacterium smegmatis. Pleurocidin was functionally
active at physiologic concentrations of magnesium and calcium; however,
high concentrations of these divalent cations ablated pleurocidin's
activity against a standard test strain, Escherichia coli
D31. Pleurocidin was tested against bacterial and fungal clinical
isolates and showed broad-spectrum antimicrobial activity. Together,
these data support the hypothesis that pleurocidin participates in
innate mucosal immunity, and it may prove to be a beneficial
therapeutic agent.
Increasing evidence suggests that
endogenous peptides with antimicrobial properties play an important
role in host defense. These peptides possess marked microbicidal
activity and have been isolated from a variety of cells of myeloid
lineage and mucosal surfaces in most species tested thus far (4,
5, 8, 12). The recent focus has been on mucus-derived peptides
and their roles in innate host defense at organism-environment
interfaces, such as the integument and the respiratory and digestive
epithelia. The multitude of peptides discovered at mucosal surfaces
include human We recently discovered pleurocidin, a novel 25-residue linear
antimicrobial peptide in the skin mucous secretions of the winter flounder, Pleuronectes americanus (6). The
sequence of the mature molecule,
GWGSFFKKAAHVGKHVGKAALTHYL, shows sequence homology with the
dermaseptin (tree frog) and ceratotoxin (medfly) classes of
antimicrobial peptides. Pleurocidin is a highly basic molecule (pI = 10.02) and is predicted to form an amphipathic Here we extend our examination of pleurocidin to the cDNA
and genomic levels and demonstrate its broad-spectrum
antimicrobial activity against a number of clinical
isolates. Transmission electron microscopy (TEM) reveals that
pleurocidin is produced within the goblet cells of the flounder small
intestine. We also examine the antimicrobial properties of pleurocidin
and reveal multiple facets of its microbicidal character targeting
pathogenic organisms. These data suggest a role for pleurocidin as a
molecular agent of fish mucosal host defense.
cDNA library construction, clone selection, and sequence.
mRNA was obtained by removing a 3- by 4-cm section of flounder skin,
quick freezing it in liquid nitrogen for 1 min, pulverizing it in a
liquid nitrogen mortar, and further grinding it with a hand-held
blender (three 10-s bursts), followed by an established procedure for
CsCl purification of RNA from tissue (2). The purified mRNA
was subsequently used in the ZAP Express cDNA synthesis kit
(Stratagene, La Jolla, Calif.) to produce inserts with 5' EcoRI and 3' XhoI restriction sites. These
inserts were then ligated into pBK-CMV phagemid vectors, packaged using
the restriction minus Gigapack III Gold packaging extract (Stratagene),
amplified in an XL1-Blue MRF' host strain, and screened with a
combination of two degenerative end-radiolabeled (with
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Characterization of a Fish Antimicrobial Peptide: Gene
Expression, Subcellular Localization, and Spectrum of
Activity
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-defensin 1 (HBD-1) in urogenital tissues
(43) and bronchoalveolar lavage fluid (39),
HBD-2 at sites of inflammation (24, 39), cryptdins from the
Paneth cells (18), tracheal antimicrobial peptide (TAP) and
lingual antimicrobial peptide (LAP) from cows (10, 33), and
magainin and PGLa from frogs (46). Each peptide class
confers a broad spectrum of antimicrobial activity and cationic charge
at physiologic pH. Many peptides show high interspecies cDNA and
protein sequence homology, frequently across evolutionarily diverse phyla.
-helix and to kill
bacteria by irreversibly rupturing their membranes.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-32P) oligonucleotide probes (degenerative sense,
5'-TTYTTYAARAARGCNGCNCAYGT-3'; inosine degenerative sense,
5'-TTYTTYAARAARGCIGCICA-3'). Inosine
(boldface) was used in the latter oligonucleotide because it can base
pair with A, C, G, or T, thus decreasing the overall degeneracy.
Putative clones from the tertiary screen were in vivo excised with
ExAssist helper phage using an XLOLR strain with kanamycin selection.
Genomic library construction, clone selection, and sequence. Flounder genomic DNA was isolated by a modification of established protocols (2). Flounder testis (1.25 g) was snap-frozen in liquid nitrogen, ground with a liquid nitrogen mortar and pestle, suspended in 15 ml of digestion buffer (100 mM NaCl, 10 mM Tris-Cl [pH 8], 25 mM EDTA [pH 8], 0.5% sodium dodecyl sulfate, 100 µg of proteinase K/ml), and incubated at 50°C for 18 h. The DNA was purified by phenol extraction (25:24:1 phenol-chloroform-isoamyl alcohol), precipitated with ammonium acetate, and eluted with TE buffer (10 mM Tris-Cl [pH 8], 0.1 mM EDTA [pH 8]), yielding 57 mg of genomic DNA. The genomic DNA (1 mg) was partially digested with Sau3AI (BamHI compatible), size fractionated in a 5 to 25% (wt/vol) NaCl gradient, and centrifuged at 37,000 rpm (55,000 × g) for 4.5 h at 25°C in a Beckman SW41 rotor. The DNA was precipitated and resuspended in 100 µl of TE buffer. Agarose (0.5% [wt/vol]) gel electrophoresis determined the fractions containing digested genomic DNA in the range of 9 to 23 kb. These correctly sized DNA fragments were ligated into an equimolar concentration of Lambda DASH II-BamHI arms (Stratagene). Packaging into Gigapack III Gold extract (Stratagene), amplification in the XL1-Blue MRA' (P2) strain (a P2 lysogenic strain which allows only recombinant phage to grow), and screening followed procedures similar to the cDNA library screening described above. The radiolabeled primers used for genomic library screening were as follows: 5AC-90c sense, 5'-GTCCTCATGGTTGAACCTGGA-3'; 5AC-90c antisense, 5'-GTCAAAAACAGTACTGGTGAT-3'; 5AC-95a sense, 5'-TGATTAGCATGTTCCTACAA-3'; and 5AC-95b sense, 5'-ACAGTTGGCAAGCATGTTGGC-3'. Clones of interest were digested with XhoI, EcoRI, HindIII, and XbaI endonucleases and subjected to Southern hybridization. Positive bands were excised and subcloned into Bluescript II SK (Stratagene), and the sequences of putative subclones were determined. The sequences were analyzed by BLAST (Basic Local Alignment Search Tool) searches against GenBank using the MacVector software package (Oxford Molecular Group).
Solid-phase pleurocidin synthesis. Pleurocidin was synthesized using solid-phase technology and purified on a reverse-phase high-performance liquid chromatography preparatory column as described previously (6). Further production and purification of solid-phase synthesized pleurocidin was performed by Robert Donnelly (Molecular Biology Core Research Facility, University of Medicine and Dentistry of New Jersey). The naturally occurring and unmodified synthetic peptides show identical MICs and minimal bactericidal concentrations (MBCs) against a standard test strain, Escherichia coli D31 (data not shown).
TEM and immunogold staining. Sections of winter flounder skin and small intestine (5 mm long by 2 mm wide by 1 mm thick) were fixed in 1.0 ml of Karnovski's fixative (4% paraformaldehyde-2% gluteraldehyde with 1× phosphate-buffered saline [PBS]) for 6 h at room temperature, washed three times with PBS, and embedded in Spurr's or Lowacryl embedding medium. Sections (800 Å thick) were fixed to nickel grids. Immunolabeling with colloidal gold conjugates followed modifications of standard methods (Nanoprobes, Inc., Stony Brook, N.Y.). The grids were submerged in distilled H2O for 7 to 8 min, incubated with 1% bovine serum albumin (BSA) in 1× PBS, pH 7.4, for 5 min at room temperature to block nonspecific protein binding sites, and incubated with a 1:5,000 dilution of preimmune serum (control) or primary polyclonal antiserum for 18 to 24 h at 4°C (the antibodies are described in reference 6). The grids were then washed with 1% BSA in PBS (three times for 1 min each time) and incubated with a 1:200 dilution of colloidal-gold-conjugated secondary goat anti-rabbit antibody for 1 h at room temperature. A final washing step in PBS preceded 1% glutaraldehyde-PBS postfixation (3 min at room temperature). The processed grids were stained in uranyl acetate-lead citrate for 15 to 20 s and examined with a Philips 300 transmission electron microscope.
Collection, typing, and conventional antibiotic testing of clinical bacterial and fungal isolates. Seventeen isolates of Candida albicans, Klebsiella pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa were obtained from patients symptomatic for urinary and respiratory tract infections, venous catheter microbial colonization, and an infected hip wound and bone. The isolates were typed by a qualified clinical microbiologist (Veterans Administration Medical Center, Houston, Tex.). The bacterial isolates were subjected to antimicrobial susceptibility testing using susceptibility cards (bioMérieux Vitek, Inc., Hazelwood, Mo.) according to the manufacturer's instructions, with MIC breakpoints based on NCCLS guidelines. The following 31 antibiotics were tested: amikacin, ampicillin, ampicillin-sublactam, aztreonam, cefazolin, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime-axetil, cefuroxime-sodium, cephalothin, ciprofloxacin, clindamycin, erythromycin, gentamicin, gentamicin 500, imipenem, nitrofurantoin, ofloxacin, oxacillin, penicillin G, piperacillin, rifampin, streptomycin 2000, tetracycline, ticarcillin, ticarcillin-CA, tobramycin, trimeth-sulfa, and vancomycin. Percent resistance to standard antibiotics was determined by the following formula: (r/t) × 100, where r is the number of antibiotics to which the test bacterium was resistant and t is the total number of antibiotics tested. Antibiotic resistance was not correlated with bacterial etiology.
Microbes and culture conditions. The clinical isolates C. albicans, K. pneumoniae, S. aureus, and P. aeruginosa and the test strain E. coli D31 were maintained on Trypticase soy agar plates with or without 5% sheep blood (Becton Dickinson and Co., Cockeysville, Md.) and cultured for 18 h in Mueller Hinton broth (MHB). Mycobacterium smegmatis (MC2155) was maintained on Trypticase soy agar plates and cultured for 60 to 72 h in basal salts minimal essential medium (1× basal salts, 1.25% glycerol, 0.5 mM CaCl2, 0.5 mM MgCl2, and 0.01% Tween).
Antimicrobial CFU microassays. The microdilution assay for MIC and MBC of Steinberg and Lehrer (41) was modified as follows. Briefly, 5 × 105 CFU/ml were incubated for 18 h at 37°C in a final volume of 55 µl of MHB with serial twofold dilutions of pleurocidin (0.2 to 100 µg/ml) in 0.01% acetic acid-0.2% BSA using 96-well polypropylene microtiter plates. Visual verification of microbial sedimentation as well as absorbance readings (600 nm) confirmed the MIC. The MBC was determined by streaking a 5-µl aliquot of the microtiter plate reaction mixture onto an MHB agar plate for the three serial dilution wells above and below the determined MIC. The lowest concentration of pleurocidin that ablated bacterial colony growth on the agar plate was deemed the MBC.
Synergy assay. M. smegmatis (MC2155) (40) was adopted as a test strain to determine the synergy between standard antibiotics and pleurocidin. Vancomycin, D-cycloserine, ethambutol, and isonicotinic acid hydrazide (INH) were tested from 0.2 to 100 µg/ml in a checkerboard fashion against pleurocidin (0.2 to 100 µg/ml) using modifications of the CFU microassay described above. The adjustments were as follows: 5.5 µl of pleurocidin, diluted in 0.01% acetic acid-0.2% BSA, and 5.5 µl of antibiotic, diluted in distilled water, were incubated with 5 × 105 CFU of M. smegmatis/ml in 44.5 µl of basal salts minimal essential medium. Since growth of M. smegmatis requires 60 to 72 h to reach stationary phase, minimal essential medium was used to reduce contaminant microbial growth. Controls were used for both standard antibiotics and pleurocidin, as well as for bacterial growth (i.e., without antibiotics).
Atomic absorption.
Mucus from a 25-cm-long winter flounder
was aspirated, diluted 1:1 in double-distilled deionized
H2O, and frozen at
20°C until use. Calcium and
magnesium concentrations were measured by flame aspiration atomic
absorption spectrophotometry (603 atomic absorption spectrophotometer;
Perkin-Elmer Foster City, Calif.) at three serial dilutions (1:50,
1:100, and 1:200). The heavy metal lanthanum, at 2% final
concentration, was used to aid in the dissociation of bound calcium.
Statistics. Bacterial colony counts (CFU assay) were performed at least in triplicate for each independent experiment. Comparison of the pleurocidin MIC with conventional antibiotic resistance was performed using a paired t test for each species of bacterium (SigmaStat; SPSS Inc., Chicago, Ill.). Unless otherwise stated, MICs are represented as geometric means.
Nucleotide sequence accession numbers. The GenBank accession numbers of the pleurocidin gene and upstream promoter sequence and the cDNA are AF210241 and AF210242, respectively.
| |
RESULTS |
|---|
|
|
|---|
Cloning and characterization of the pleurocidin gene and cDNA.
A cDNA library was constructed from winter flounder skin mRNA.
End-radiolabeled degenerative oligonucleotide probes, derived from
reverse translation of mature pleurocidin protein sequence, were used
to screen the skin cDNA library. A single clone hybridized, and primer
extension followed by dideoxynucleotide sequencing determined the
length (317 nucleotides) and sequence of pleurocidin cDNA (Fig.
1).
|
56 and
200, respectively (MacVector; Oxford Molecular
Group). Further analysis suggests the presence of binding sites for
numerous transcription factors, including NF-IL6, gamma interferon
(IFN-
) response element, IFN-
response element, Oct 1, and HNF-1.
|
Ultrastructural localization of pleurocidin in flounder skin and
intestine.
Winter flounder skin was examined for cellular
localization of pleurocidin by immunolabeling and analyzed by TEM. The
immunogold electron microscopy exhibited labeling (gold particles) in
the mucus-producing cells of the flounder skin. The photomicrograph in
Fig. 3A shows a low-magnification image
of a section of flounder skin with one intact mucous cell. Gold
particles are seen evenly dispersed throughout the mucin granules
within the cytoplasm and concentrated at the periphery. Under
this magnification, the labeling indicates preferential location of
pleurocidin near the mucin granule membranes rather than in the
intragranule domain. Figure 3A (inset) is a high-magnification electron
micrograph of the goblet cell with representative gold particles
indicated. A control, using preimmune serum, is shown in Fig. 3B and
indicates the specificity of the labeling.
|
Human pathogens display varied sensitivities to pleurocidin.
Seventeen bacterial and fungal isolates were typed and cultured from
clinically infected patients. To determine antimicrobial susceptibility, each isolate was tested with Vitek susceptibility cards
containing conventional antibiotics to which respective standard typed
strains are sensitive. The resistance of clinical isolates to
conventional antibiotics ranged from 5 to 73% of antibiotics tested,
with the most resistant isolates being K. pneumoniae 10808 and S. aureus 8580 (Table 1).
To determine the activity of pleurocidin, the clinical isolates
described above were incubated with pleurocidin in a CFU microassay
(41). Most notably, all four isolates of the opportunistic
fungus C. albicans were highly susceptible to pleurocidin.
Although several strains that were highly resistant to standard
antibiotics were also insensitive to pleurocidin (e.g., K. pneumoniae 10808 and S. aureus 8580; P < 0.05), there was not a significant correlation between
standard antibiotic resistance and the pleurocidin MIC. This would
suggest that pleurocidin acts via a different mechanism than the
other tested antibiotics.
|
Pleurocidin acts synergistically with
D-cycloserine.
Pleurocidin was subjected to a CFU
microassay in the presence and absence of antibiotics effective against
Mycobacterium spp. to identify antimicrobial substances
synergistic against M. smegmatis. M. smegmatis was chosen as
a model for the clinically relevant Mycobacterium
tuberculosis because of its low infection risk and relatively
short incubation time (40). Pleurocidin was tested in a
checkerboard fashion with D-cycloserine, vancomycin,
ethambutol, or INH against M. smegmatis. In combination, the
MICs of pleurocidin and D-cycloserine were each reduced
fourfold (Fig. 4). Investigation of
vancomycin, ethambutol, and INH indicated that their microbicidal effects were merely additive (data not shown). The MBC was equivalent to the MIC in all analyses. Antagonism was not detected for any combination tested.
|
Pleurocidin is insensitive to physiologic concentrations of
magnesium and calcium.
Magnesium and calcium were added to
determine their effects on the MICs of pleurocidin. Magnesium and
calcium have been reported to inhibit the mammalian antimicrobial
peptide defensin (20, 36), possibly by acting to increase
bacterial membrane stabilization (7), thus regulating
the microbicidal function. We noticed a similar trend in that an
increased calcium or magnesium concentration resulted in deceased
antimicrobial activity against the standard test strain, E. coli D31 (Table 2). NaCl, added at
concentrations 15-fold greater than those of either MgCl2
or CaCl2, did not affect the microbicidal activity of
pleurocidin, demonstrating that chloride ion was not the inhibiting
factor. Winter flounder mucus calcium and magnesium
concentrations, as measured by atomic absorption, were 0.68 mM
magnesium and 0.36 mM calcium (data not shown). These values are within
the functional range of pleurocidin and comparable to concentrations in
human tracheal secretory gland cells (35).
|
| |
DISCUSSION |
|---|
|
|
|---|
Ultrastructural analyses were performed to identify the cellular distribution or compartmentalization of mature pleurocidin. Immunogold TEM confirmed immunohistochemical data in localizing pleurocidin to the flounder skin mucous cells, and the finding of pleurocidin in goblet cells of the small intestine lends credence to pleurocidin's role in mucosal immunity. This is not surprising, since the gut, like the epidermis, is an interface between the organism and the environment. However, immunogold TEM may also offer an additional explanation for pleurocidin's location and activity. The localization of pleurocidin primarily on the outer margins of mucin granules within the skin mucous cells deserves attention, as this may suggest regional accumulation of the peptide. Whether pleurocidin is stored as an active mature peptide or an inactive proform has yet to be determined.
Many antimicrobial peptides are formed from precursor proteins in which an anionic propeptide is involved in cellular trafficking and charge neutralization of the mature peptide (13, 26, 34, 42, 45). Although most antimicrobial peptides have a propeptide NH2 terminal to the mature peptide, pleurocidin is predicted to have an anionic propeptide COOH terminal to the mature region. This configuration, although rare, is also found in preprotachyplesins from the hemocytes of horseshoe crabs (17) and in preprostyelins from tunicates (47). The four cationic residues in the mature peptide region and the four anionic residues in the proregion of pleurocidin suggest that pleurocidin's propeptide is involved in charge neutralization of the mature region. Posttranslational enzymatic cleavage (13) could thus release the propiece and activate pleurocidin.
Genomic analysis of the pleurocidin gene reveals a four-exon structure,
where the mature peptide is encoded by exons 2, 3, and 4, with the
C-terminal propiece encoded by exon 4. Computer-based analysis
(MacVector) of the 5' flanking region indicated the presence of typical
transcriptional promoter elements, including TATA and CAAT boxes. Also
noted were consensus binding sequences for a number of transcription
factors found in the promoter regions of host response genes in
mammals, including NF-IL6 and IFN-
and -
response elements. These
consensus sequences have been found in the promoter regions of other
fish genes, including the transferrin gene in salmon (19),
the interferon-inducible Mx genes in trout (21), the
insulinlike growth factor gene in trout (37), and the
antifreeze protein gene in flounder (25). Activation of such
transcription factors and binding to their consensus sequences have
also been observed in fish (25, 31, 32). This suggests that
the flounder may regulate pleurocidin gene expression in response to
infection and inflammation, in a manner similar to that seen for
antimicrobial peptide genes from amphibians (27, 38),
insects (11), and mammals (9).
In previous studies (6), we characterized the activity of pleurocidin against standard test strains of nonpathogenic bacteria. We show here that pleurocidin notably exhibits both anticandidal and antibacterial activity against clinical isolates, which may decrease the chance of candidal superinfections normally associated with antibacterial treatment of conditions such as urinary tract infections, bacterial meningitis, and bacterial vaginosis (15, 29, 30). Pleurocidin may prove beneficial in the treatment or prevention of sequelae.
Antimicrobial peptides have been shown to act in concert with other
microbicidal agents. NP-1, a
-sheet rabbit neutrophil peptide, acts
synergistically with BPI (bactericidal/ permeability-increasing protein) when acting against E. coli J5 (22) and
with fluconazole when acting against Cryptococcus neoformans
(1). The antimicrobial peptides magainin-2 and PGLa from the
skin of Xenopus laevis show a markedly increased effect when
combined to target E. coli or tumor cells (44).
The present study reveals synergy between a standard antibiotic and
pleurocidin targeting M. smegmatis. Mycobacterium spp. have
extraordinarily thick mycolic acid outer walls that are not easily
penetrated by perforating molecules such as antimicrobial peptides.
Although pleurocidin alone did not show appreciable antibacterial
activity against M. smegmatis, its bactericidal activity was
enhanced by the presence of D-cycloserine. D-Cycloserine acts as an inhibitor of cell wall synthesis
and has been shown to increase mycobacterial susceptibility to other agents (28). Although D-cycloserine is an
effective antimicrobial agent, it is rarely prescribed due to adverse
neurological effects. Pleurocidin may therefore prove useful in
reducing the toxicity of D-cycloserine.
In further characterizing the action of pleurocidin, we discovered that divalent magnesium and calcium (but not monovalent sodium) inhibit its antimicrobial activity. The actions of several other antimicrobial peptides are inhibited by high concentrations of monovalent and divalent salts (3, 20, 36). Stabilizing divalent cations, such as magnesium and calcium, are intimately associated with lipopolysaccharides in the outer leaflets of gram-negative bacteria (7). Candidacidal activity by NP-1 is inhibited by increasing the Ca2+ concentration of the incubation mixtures but is relatively unaffected by Mg2+ (36). Although calcium is not involved in the initial effects on the plasma membrane, varying the calcium concentration altered the later effects of defensin-treated K562 tumor cell lysis (23). Since the concentrations of both magnesium and calcium in seawater (10.0 and 52.3 mM, respectively) are much higher than physiologic concentrations in mucus, pleurocidin is likely active within the mucus proper and not at the environment interface. The reported concentrations of magnesium and calcium in human body fluids are on the order of 1 mM, which is within the active, and thus possibly therapeutic, antimicrobial range of pleurocidin.
In summary, we have characterized the gene, antimicrobial activity, and ultrastructural location of the antimicrobial peptide pleurocidin. Although we have established the antimicrobial spectrum of pleurocidin against several pathogenic clinical isolates and further characterized its activity, additional studies are necessary to determine its therapeutic benefits.
| |
ACKNOWLEDGMENTS |
|---|
We thank Francis Walter Kemp for his excellent work on atomic absorption measurements; Peddrick Weis, Noel Espina, and Michael R. Condon for invaluable technical assistance; and Richard D. Howland for statistical guidance.
This work was supported in part by the National Oceanic and Atmospheric Administration, Office of Sea Grant and Extramural Programs, Department of Commerce (grant NA36RG050; Project R/N-95003).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Anatomy, Cell Biology and Injury Sciences, University of Medicine and Dentistry of New Jersey, MSB-G604, 185 South Orange Ave., Newark, NJ 07103. Phone: (973) 972-3324. Fax: (973) 972-7489. E-mail: gdiamond{at}umdnj.edu.
New Jersey Sea Grant Publication NJSG-00-441.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Alcouloumre, M. S.,
M. A. Ghannoum,
A. S. Ibrahim,
M. E. Selsted, and J. E. J. Edwards.
1993.
Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro.
Antimicrob. Agents Chemother.
37:2628-2632 |
| 2. | Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 1996. Current protocols in molecular biology. John Wiley & Sons, Inc., New York, N.Y. |
| 3. |
Bals, R.,
X. Wang,
Z. Wu,
T. Freeman,
V. Bafna,
M. Zasloff, and J. M. Wilson.
1998.
Human -defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung.
J. Clin. Investig.
102:874-880[Medline].
|
| 4. | Bevins, C. L. 1994. Antimicrobial peptides as agents of mucosal immunity. Ciba Found. Symp. 186:250-269[Medline]. |
| 5. | Boman, H. G. 1996. Peptide antibiotics: holy or heretic grails of innate immunity? Scand. J. Immunol. 43:475-482[CrossRef][Medline]. |
| 6. |
Cole, A. M.,
P. Weis, and G. Diamond.
1997.
Isolation and characterization of pleurocidin, an antimicrobial peptide in the skin secretions of winter flounder.
J. Biol. Chem.
272:12008-12013 |
| 7. | Coughlin, R. T., S. Tonsager, and E. J. McGroarty. 1983. Quantitation of metal cations bound to membranes and extracted lipopolysaccharide of Escherichia coli. Biochemistry 22:2002-2007[CrossRef][Medline]. |
| 8. |
Diamond, G., and C. L. Bevins.
1998.
-Defensins: endogenous antibiotics of the innate host defense response.
Clin. Immunol. Immunopathol.
88:221-225[CrossRef][Medline].
|
| 9. |
Diamond, G.,
V. Kaiser,
J. Rhodes,
J. P. Russell, and C. L. Bevins.
2000.
Transcriptional regulation of -defensin gene expression in tracheal epithelial cells.
Infect. Immun.
68:113-119 |
| 10. |
Diamond, G.,
M. Zasloff,
H. Eck,
M. Brasseur,
W. L. Maloy, and C. L. Bevins.
1991.
Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA.
Proc. Natl. Acad. Sci. USA
88:3952-3956 |
| 11. | Engstrom, Y., L. Kadalayil, S. C. Sun, C. Samakovlis, D. Hultmark, and I. Faye. 1993. Kappa B-like motifs regulate the induction of immune genes in Drosophila. J. Mol. Biol. 232:327-333[CrossRef][Medline]. |
| 12. | Ganz, T., and R. I. Lehrer. 1994. Defensins. Curr. Opin. Immunol. 6:584-589[CrossRef][Medline]. |
| 13. |
Ganz, T.,
L. Liu,
E. V. Valore, and A. Oren.
1993.
Posttranslational processing and targeting of transgenic human defensin in murine granulocyte, macrophage, fibroblast, and pituitary adenoma cell lines.
Blood
82:641-650 |
| 14. | Ganz, T., and J. Weiss. 1997. Antimicrobial peptides of phagocytes and epithelia. Semin. Hematol. 34:343-354[Medline]. |
| 15. | Gelfand, M. S., Z. A. McGee, A. B. Kaiser, F. P. Tally, and J. Moses. 1990. Candidal meningitis following bacterial meningitis. South. Med. J. 83:567-570[Medline]. |
| 16. |
Gudmundsson, G. H.,
K. P. Magnusson,
B. P. Chowdhary,
M. Johansson,
L. Andersson, and H. G. Boman.
1995.
Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL-39.
Proc. Natl. Acad. Sci. USA
92:7085-7089 |
| 17. |
Iwanaga, S.,
S. Kawabata, and T. Muta.
1998.
New types of clotting factors and defense molecules found in horseshoe crab hemolymph: their structures and functions.
J. Biochem. (Tokyo)
123:1-15 |
| 18. |
Jones, D. E., and C. L. Bevins.
1992.
Paneth cells of the human small intestine express an antimicrobial peptide gene.
J. Biol. Chem.
267:23216-23225 |
| 19. | Kvingedal, A. M. 1994. Characterization of the 5' region of the Atlantic salmon (Salmo salar) transferrin-encoding gene. Gene 150:335-339[CrossRef][Medline]. |
| 20. | Lehrer, R. I., T. Ganz, D. Szklarek, and M. E. Selsted. 1988. Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. J. Clin. Investig. 81:1829-1835. |
| 21. | Leong, J. C., G. D. Trobridge, C. H. Kim, M. Johnson, and B. Simon. 1998. Interferon-inducible Mx proteins in fish. Immunol. Rev. 166:349-363[CrossRef][Medline]. |
| 22. | Levy, O., C. E. Ooi, J. Weiss, R. I. Lehrer, and P. Elsbach. 1994. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J. Clin. Investig. 94:672-682. |
| 23. | Lichtenstein, A. 1991. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J. Clin. Investig. 88:93-100. |
| 24. |
Liu, L.,
L. Wang,
H. P. Jia,
C. Zhao,
H. H. Q. Heng,
B. C. Schutte,
P. B. McCray, and T. Ganz.
1998.
Structure and mapping of the human -defensin HBD-2 gene and its expression at sites of inflammation.
Gene
222:237-244[CrossRef][Medline].
|
| 25. | Miao, M., S. L. Chan, C. L. Hew, and G. L. Fletcher. 1998. Identification of nuclear proteins interacting with the liver-specific enhancer B element of the antifreeze protein gene in winter flounder. Mol. Mar. Biol. Biotechnol. 7:197-203[Medline]. |
| 26. | Michaelson, D., J. Rayner, M. Couto, and T. Ganz. 1992. Cationic defensins arise from charge-neutralized propeptides: a mechanism for avoiding leukocyte autocytotoxicity? J. Leukoc. Biol. 51:634-639[Abstract]. |
| 27. |
Miele, R.,
D. Ponti,
H. G. Boman,
D. Barra, and M. Simmaco.
1998.
Molecular cloning of a bombinin gene from Bombina orientalis: detection of NF- B and NF-IL6 binding sites in its promoter.
FEBS Lett.
431:23-28[CrossRef][Medline].
|
| 28. |
Rastogi, N.,
K. S. Goh, and H. L. David.
1990.
Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis.
Antimicrob. Agents Chemother.
34:759-764 |
| 29. | Redondo-Lopez, V., C. Meriwether, C. Schmitt, M. Opitz, R. Cook, and J. D. Sobel. 1990. Vulvovaginal candidiasis complicating recurrent bacterial vaginosis. Sex. Transm. Dis. 17:51-53[Medline]. |
| 30. |
Romero-Vivas, J.,
M. Rodriguez-Creixems,
E. Bouza,
T. Hellin,
A. Guerrero,
J. Martinez-Beltran, and M. Garcia de la Torre.
1985.
Evaluation of aztreonam in the treatment of severe bacterial infections.
Antimicrob. Agents Chemother.
28:222-226 |
| 31. | Ross, D. A., M. Lyles, B. E. Ledford, B. G. Magor, M. R. Wilson, N. W. Miller, L. W. Clem, D. A. Middleton, and G. W. Warr. 1999. Catfish Oct2 binding affinity and functional preference for octamer motifs, and interaction with OBF-1. Dev. Comp. Immunol. 23:199-211[CrossRef][Medline]. |
| 32. | Rycyzyn, M. A., M. R. Wilson, E. Bengten, G. W. Warr, L. W. Clem, and N. W. Miller. 1998. Mitogen and growth factor-induced activation of a STAT-like molecule in channel catfish lymphoid cells. Mol. Immunol. 35:127-136[CrossRef][Medline]. |
| 33. |
Schonwetter, B. S.,
E. D. Stolzenberg, and M. A. Zasloff.
1995.
Epithelial antibiotics induced at sites of inflammation.
Science
267:1645-1648 |
| 34. | Scocchi, M., B. Skerlavaj, D. Romeo, and R. Gennaro. 1992. Proteolytic cleavage by neutrophil elastase converts inactive storage proforms to antibacterial bactenecins. Eur. J. Biochem. 209:589-595[Medline]. |
| 35. | Sebille, S., M. Pereira, J. M. Millot, J. Jacquot, A. M. Delabroise, M. Arnaud, and M. Manfait. 1998. Extracellular Mg2+ inhibits both histamine-stimulated Ca(2+)-signaling and exocytosis in human tracheal secretory gland cells. Biochem. Biophys. Res. Commun. 246:111-116[CrossRef][Medline]. |
| 36. | Selsted, M. E., S. S. Harwig, T. Ganz, J. W. Schilling, and R. I. Lehrer. 1985. Primary structures of three human neutrophil defensins. J. Clin. Investig. 76:1436-1439. |
| 37. | Shamblott, M. J., S. Leung, M. W. Greene, and T. T. Chen. 1998. Characterization of a teleost insulin-like growth factor II (IGF-II) gene: evidence for promoter CCAAT/enhancer-binding protein (C/EBP) sites, and the presence of hepatic C/EBP. Mol. Mar. Biol. Biotechnol. 7:181-190[Medline]. |
| 38. | Simmaco, M., A. Boman, M. L. Mangoni, G. Mignogna, R. Miele, D. Barra, and H. G. Boman. 1997. Effect of glucocorticoids on the synthesis of antimicrobial peptides in amphibian skin. FEBS Lett. 416:273-275[CrossRef][Medline]. |
| 39. |
Singh, P. K.,
H. P. Jian,
K. Wiles,
J. Hesselberth,
L. Liu,
B. D. Conway,
E. P. Greenberg,
E. V. Valore,
M. J. Welsh,
T. Ganz,
B. F. Tack, and P. B. J. McCray.
1998.
Production of -defensins by human airway epithelia.
Proc. Natl. Acad. Sci. USA
95:14961-14966 |
| 40. | Snapper, S. B., R. E. Melton, S. Mustafa, T. Kieser, and W. R. J. Jacobs. 1990. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol. Microbiol. 4:1911-1919[Medline]. |
| 41. | Steinberg, D. A., and R. I. Lehrer. 1997. Designer assays for antimicrobial peptides. Disputing the "one-size-fits-all" theory. Methods Mol. Biol. 78:169-186[Medline]. |
| 42. | Valore, E. V., E. Martin, S. S. Harwig, and T. Ganz. 1996. Intramolecular inhibition of human defensin HNP-1 by its propiece. J. Clin. Investig. 97:1624-1629[Medline]. |
| 43. |
Valore, E. V.,
C. H. Park,
A. J. Quayle,
K. R. Wiles,
P. B. McCray, and T. Ganz.
1998.
Human -defensin-1: an antimicrobial peptide of urogenital tissues.
J. Clin. Investig.
101:1633-1642[Medline].
|
| 44. | Westerhoff, H. V., M. Zasloff, J. L. Rosner, R. W. Hendler, A. De Waal, A. Vaz Gomes, P. M. Jongsma, A. Riethorst, and D. Juretic. 1995. Functional synergism of the magainins PGLa and magainin-2 in Escherichia coli, tumor cells and liposomes. Eur. J. Biochem. 228:257-264[Medline]. |
| 45. |
Zanetti, M.,
L. Litteri,
R. Gennaro,
H. Horstmann, and D. Romeo.
1990.
Bactenecins, defense polypeptides of bovine neutrophils, are generated from precursor molecules stored in the large granules.
J. Cell Biol.
111:1363-1371 |
| 46. | Zasloff, M. 1992. Antibiotic peptides as mediators of innate immunity. Curr. Opin. Immunol. 4:3-7[CrossRef][Medline]. |
| 47. | Zhao, C. Q., L. Liaw, I. H. Lee, and R. I. Lehrer. 1997. cDNA cloning of three cecropin-like antimicrobial peptides (Styelins) from the tunicate, Styela clava. FEBS Lett. 412:144-148[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |